Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: InSite Vision/Bausch & Lomb

Executive Summary

InSite Vision/Bausch & Lomb: Announce global agreement covering the manufacturing of potential InSite Vision products, the worldwide marketing of PilaSite (pilocarpine) for glaucoma and joint development of the DuraSite eyedrop-based sustained drug delivery system. B&L will make a $2 mil. equity investment, provide up to $2 mil. in R&D funding and pay royalties on future products. PilaSite and BetaSite (levobunolol) for glaucoma both have completed Phase III trials, Alameda, Calif.-based InSite notes; the B&L deal will allow the products to proceed to NDA filings "without incurring substantial infrastructure costs required to develop our own large-scale production facilities," InSite notes...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel